Cargando…

Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease

BACKGROUND: A three-drug regimen (macrolide, ethambutol, and rifampicin) is recommended for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). Although macrolide has proven efficacy, the role of ethambutol and rifampicin in patients without acquired immune deficiency syndrome i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung-Jun, Lee, Jong Sik, Kwak, Nakwon, Cho, Jaeyoung, Lee, Chang-Hoon, Han, Sung Koo, Yim, Jae-Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849249/ https://www.ncbi.nlm.nih.gov/pubmed/31711459 http://dx.doi.org/10.1186/s12890-019-0982-8

Ejemplares similares

Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease
por: Kim, Joong-Yub, et al.
Publicado: (2022)

Combined administration of rifampicin, ethambutol, and clarithromycin for the treatment of tenosynovitis of the hand caused by Mycobacterium avium complex: Case series and literature review
por: Kaji, Yoshio, et al.
Publicado: (2021)

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol
por: Nakamura, Kayo, et al.
Publicado: (2023)

The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023)

Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease
por: Kwon, Yong Shik, et al.
Publicado: (2020)

Blood Agar Validation for Susceptibility Testing of Isoniazid, Rifampicin, Ethambutol, and Streptomycin to Mycobacterium tuberculosis Isolates
por: Coban, Ahmet Yilmaz
Publicado: (2013)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

New-onset nontuberculous mycobacterial pulmonary disease in bronchiectasis: tracking the clinical and radiographic changes
por: Kwak, Nakwon, et al.
Publicado: (2020)

Therapeutic implications of nano-encapsulated rifabutin, azithromycin & ethambutol against experimental Mycobacterium avium infection in mice
por: Grewal, Tapinder Kaur, et al.
Publicado: (2018)

Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia
por: Tessema, Belay, et al.
Publicado: (2012)

Consolidations in Nodular Bronchiectatic Mycobacterium Avium Complex Lung Disease: Mycobacterium Avium Complex or Other Infection?
por: Im, Soo Ah, et al.
Publicado: (2010)

The Association Between Bacille Calmette-Guérin Vaccination and Nontuberculous Mycobacterial Pulmonary Disease
por: Kwak, Nakwon, et al.
Publicado: (2022)

Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol
por: Nakagawa, Taku, et al.
Publicado: (2019)

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
por: Nardotto, Glauco Henrique Balthazar, et al.
Publicado: (2021)

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
por: Sibley, Laura, et al.
Publicado: (2022)

Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model
por: Cha, Seung Bin, et al.
Publicado: (2015)

Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study
por: Kwak, Nakwon, et al.
Publicado: (2020)

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial
por: Lee, Ji Yeon, et al.
Publicado: (2017)

Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease
por: Kim, Eun Young, et al.
Publicado: (2011)

Treatment of Mycobacterium avium Complex Pulmonary Disease
por: Kwon, Yong-Soo, et al.
Publicado: (2019)

Effect of COVID-19 on Tuberculosis Notification, South Korea
por: Kwak, Nakwon, et al.
Publicado: (2020)

In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using Mycobacterium tuberculosis isolates
por: Hemvani, Nanda, et al.
Publicado: (2012)

Impact of prognostic nutritional index on outcomes in patients with Mycobacterium avium complex pulmonary disease
por: Moon, Sung Woo, et al.
Publicado: (2020)

Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes
por: Shimomura, Hitoshi, et al.
Publicado: (2015)

Endobronchial Mycobacterium avium Infection in an Immunocompetent Patient
por: Kang, Seung-Hwa, et al.
Publicado: (2013)

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey
por: van Ingen, Jakko, et al.
Publicado: (2020)

Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of Mycobacterium abscessus Pulmonary Disease
por: Park, Youngmok, et al.
Publicado: (2021)

Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
por: Kwak, Nakwon, et al.
Publicado: (2022)

Agranulocytosis Induced by Ethambutol in a Patient with Pulmonary Tuberculosis
por: Moon, Kyoung Min, et al.
Publicado: (2015)

Myosteatosis as a prognostic factor of Mycobacterium avium complex pulmonary disease
por: Chung, Eunki, et al.
Publicado: (2023)

Clinical Implications of Size of Cavities in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Single-Center Cohort Study
por: Kang, Hye-Rin, et al.
Publicado: (2021)

A Rapid Assessing Method of Drug Susceptibility Using Flow Cytometry for Mycobacterium tuberculosis Isolates Resistant to Isoniazid, Rifampin, and Ethambutol
por: Lee, Sun-Kyoung, et al.
Publicado: (2022)

Characteristics of Circulating CD4(+) T Cell Subsets in Patients with Mycobacterium avium Complex Pulmonary Disease
por: Han, Sun Ae, et al.
Publicado: (2020)

Prognostic impact of malignant diseases in idiopathic pulmonary fibrosis
por: Lee, Hong Yeul, et al.
Publicado: (2020)

Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection
por: Lee, Ju Mi, et al.
Publicado: (2023)

A marmoset model for Mycobacterium avium complex pulmonary disease
por: Peters, Jay, et al.
Publicado: (2023)

Pulmonary Mycobacterium avium Complex Infection Showing Extensive Consolidation
por: Yamazoe, Masami, et al.
Publicado: (2022)

Utility of the REBA MTB-rifa® assay for rapid detection of rifampicin resistant Mycobacterium Tuberculosis
por: Cho, Eunjin, et al.
Publicado: (2013)

Ethambutol resistance of indigenous Mycobacterium tuberculosis isolated from human patients
por: Nazir¹, Taha, et al.
Publicado: (2010)

Usefulness of Post-bronchoscopy Sputum Culture for Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease
por: Gu, Kang-Mo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b52a8gkoqg34s906qjsdb4ee9p